Clostridium difficile and the microbiota
Open accessThe DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
Clostridium difficile infection (CDI) is the leading health care-associated illness. Both human and animal models have demonstrated the importance of the gut microbiota's capability of providing colonization resistance against C. difficile. Risk factors for disease development include antibiotic use, which disrupts the gut microbiota, leading to the loss of colonization resistance and subsequent CDI. Identification of the specific microbes capable of restoring this function remains elusive. Future studies directed at how microbial communities influence the metabolic environment may help elucidate the role of the microbiota in disease development. These findings will improve current biotherapeutics for patients with CDI, particularly those with recurrent disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These concepts of manipulating commensal–pathogen competition for nutrients, such as iron, may also prove relevant to C. difficile infection, where faecal microbial transfer has had therapeutic success through normalization of the commensal microbiota. 149 , 176”
From The battle for iron in enteric infections (2020) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 3×
“Clostridium cluster XIVa (64, 76): Proteus spp.”
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872 · cited 1×
“Various microbes have also been observed to impact subsets of T cells, such as the induction of Tregs by Clostridium species (57) and Th17 cell differentiation by segmented filamentous bacteria (58).”
BackgroundDethlefsen, L., & Relman, D. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000087107 · Cited by 2,421 · cited 1×
“Dethlefsen et al. found that although recovery began within weeks of ciprofloxacin cessation, the new community did not necessarily include all community members observed before antibiotic use (36).”
BackgroundDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“although compositional changes may be dependent on the antibiotic used as well as the underlying microbiota community of the individual (34, 35).”
BackgroundReduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., et al. (2006) · Gut · doi:10.1136/gut.2005.073817 · Cited by 2,277 · cited 1×
“A decreased diversity of Firmicutes and Bacteroidetes has been observed in the microbiota of IBD patients (50).”
BackgroundLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946 · cited 1×
“These increases in CDI burden have occurred in conjunction with the emergence of hyperendemic strains (4, 5).”
BackgroundComposition, variability, and temporal stability of the intestinal microbiota of the elderly
Claesson, M. J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery, E., Marchesi, J. R., Falush, D., Dinan, T., Fitzgerald, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000097107 · Cited by 1,754 · cited 6×
“Using nonsequencing methods, Hopkins et al. observed that elderly patients with CDI had higher counts of Enterobacteriaceae (Proteobacteria), Enterococcus , and Lactobacillus (both Firmicutes), whereas healthy elderly patients harbored more diverse Bacteroides strains (Bacteroide-table od, fecal microbiota transplanta…”
BackgroundInfluentialThrough Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians
Biagi, E., Nylund, L., Candela, M., Ostan, R., Bucci, L., Pini, E., Nikkïla, J., Monti, D., Satokari, R., Franceschi, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010667 · Cited by 1,483 · cited 1×
“The human gut microbiome undergoes extreme changes throughout life, and it is not surprising that shifts in the microbial composition have been observed in elderly people (38, 39).”
BackgroundGaboriau-Routhiau, V., Rakotobe, S., Lécuyer, E., Mulder, I., Lan, A., Bridonneau, C., Rochet, V., Pisi, A., De Paepe, M., Brandi, G., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.020 · Cited by 1,452 · cited 1×
“Various microbes have also been observed to impact subsets of T cells, such as the induction of Tregs by Clostridium species (57) and Th17 cell differentiation by segmented filamentous bacteria (58).”
Background
Cited by
Host Biology in Light of the Microbiome: Ten Principles of Holobionts and Hologenomes
Bordenstein, S. R., & Theis, K. R. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002226 · Cited by 1,240
Mechanisms and consequences of intestinal dysbiosis
Weiss, G. A., & Hennet, T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2509-x · Cited by 775
“Dysbiosis can trigger disease in the first weeks of life as observed in necrotizing enterocolitis [14], during adulthood through the promotion of colorectal cancer [15], or in elderly people as exemplified by Clostridium difficile-associated diarrhea [16].”
BackgroundAntibiotics in early life and obesity
Cox, L. M., & Blaser, M. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.210 · Cited by 541
Regional Diversity of the Gastrointestinal Microbiome
Martinez-Guryn, K., Leone, V., & Chang, E. B. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.011 · Cited by 465
“difficile has been observed at low levels in healthy humans, particularly infants, antibiotic-induced disruption of the indigenous colonic microbiota and resulting increases in colonic primary bile acid concentrations promote its outgrowth, toxin production, and invasion (Seekatz and Young, 2014).”
BackgroundCurrent Sampling Methods for Gut Microbiota: A Call for More Precise Devices
Tang, Q., Jin, G., Wang, G., Liu, T., Liu, X., Wang, B., & Cao, H. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00151 · Cited by 455
Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes
Wen, L., & Duffy, A. (2017) · The Journal of Nutrition · doi:10.3945/jn.116.240754 · Cited by 412
“difficile infection is a typical result of severe dysbiosis in the gut microbiota (71, 72).”
BackgroundNakajima, M., Arimatsu, K., Kato, T., Matsuda, Y., Minagawa, T., Takahashi, N., Ohno, H., & Yamazaki, K. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134234 · Cited by 382
“Although Clostridium difficile is a well-known pathogenic bacterium that induces colitis [31], the identified bacteria had less than 97% similarity in the 16S rRNA gene with Clostridium difficile and therefore was considered to belong to a different taxon.”
BackgroundBlaser, M. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78366 · Cited by 297
“Seekatz and Young discuss potential relationships between C. difficile , a human commensal that has become a pathogen, and other members of the human gut microbiota (43).”
Milani, C., Ticinesi, A., Gerritsen, J., Nouvenne, A., Lugli, G. A., Mancabelli, L., Turroni, F., Duranti, S., Mangifesta, M., Viappiani, A., et al. (2016) · Scientific Reports · doi:10.1038/srep25945 · Cited by 217
The promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217
Louie, T., Golan, Y., Khanna, S., Bobilev, D., Erpelding, N., Fratazzi, C., Carini, M., Menon, R., Ruisi, M., Norman, J. M., et al. (2023) · JAMA · doi:10.1001/jama.2023.4314 · Cited by 203
Virulence factors of Clostridium difficile and their role during infection
Janoir, C. (2015) · Anaerobe · doi:10.1016/j.anaerobe.2015.10.009 · Cited by 196
How to: establish and run a stool bank
Terveer, E. M., van Beurden, Y. H., Goorhuis, A., Seegers, J. F. M. L., Bauer, M. P., van Nood, E., Dijkgraaf, M. G. W., Mulder, C. J. J., Vandenbroucke-Grauls, C. M. J. E., Verspaget, H. W., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.05.015 · Cited by 168
“Recurrences are associated with clinically severe diarrhoea and persistent disturbance of the colonic microbiota [4].”
BackgroundGut microbiota, dietary intakes and intestinal permeability reflected by serum zonulin in women
Mörkl, S., Lackner, S., Meinitzer, A., Mangge, H., Lehofer, M., Halwachs, B., Gorkiewicz, G., Kashofer, K., Painold, A., Holl, A. K., et al. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1784-0 · Cited by 150
Seekatz, A. M., Theriot, C. M., Molloy, C. T., Wozniak, K. L., Bergin, I. L., & Young, V. B. (2015) · Infection and Immunity · doi:10.1128/iai.00459-15 · Cited by 143
“Paradoxically, this may further perturb the intestinal microbial community (10, 11).”
BackgroundSelf-citationDubberke, E. R., Lee, C. H., Orenstein, R., Khanna, S., Hecht, G., & Gerding, D. N. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy259 · Cited by 140
The esophageal microbiota in health and disease
Di Pilato, V., Freschi, G., Ringressi, M. N., Pallecchi, L., Rossolini, G. M., & Bechi, P. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13127 · Cited by 139
“2015 12 BE (12) – EAC Culture-independent”
IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection
Frisbee, A. L., Saleh, M. M., Young, M. K., Leslie, J. L., Simpson, M. D., Abhyankar, M. M., Cowardin, C. A., Ma, J. Z., Pramoonjago, P., Turner, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10733-9 · Cited by 134
Embracing the gut microbiota: the new frontier for inflammatory and infectious diseases
van den Elsen, L. W., Poyntz, H. C., Weyrich, L. S., Young, W., & Forbes‐Blom, E. E. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2016.91 · Cited by 126
Khanna, S., Montassier, E., Schmidt, B., Patel, R., Knights, D., Pardi, D. S., & Kashyap, P. C. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13750 · Cited by 124
“difficile in adult patients.(27) Faecalibacterium prausnitzii is largely considered a beneficial bacterium as significant reductions in this taxa have been reported in patients with inflammatory bowel disease compared to healthy individuals.”
Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?
Quigley, E. M. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.29 · Cited by 125
Henn, M. R., O’Brien, E. J., Diao, L., Feagan, B. G., Sandborn, W. J., Huttenhower, C., Wortman, J. R., McGovern, B. H., Wang-Weigand, S., Lichter, D. I., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.07.048 · Cited by 118
Brown, J. R.-M., Flemer, B., Joyce, S. A., Zulquernain, A., Sheehan, D., Shanahan, F., & O’Toole, P. W. (2018) · BMC Gastroenterology · doi:10.1186/s12876-018-0860-5 · Cited by 99
Sokol, H., Jegou, S., McQuitty, C., Straub, M., Leducq, V., Landman, C., Kirchgesner, J., Le Gall, G., Bourrier, A., Nion-Larmurier, I., et al. (2018) · Gut Microbes · doi:10.1080/19490976.2017.1361092 · Cited by 100
“For example, Bifidobacterium and members of Clostridium clusters IV and XIVa (such as Faecalibacterium prausnitzii or Roseburia intestinalis) were decreased, while Enterobacteriaceae and Enterococcus were increased.(5)”
BackgroundThe Oral-Lung Axis: The Impact of Oral Health on Lung Health
Gaeckle, N. T., Pragman, A. A., Pendleton, K. M., Baldomero, A. K., & Criner, G. J. (2020) · Respiratory Care · doi:10.4187/respcare.07332 · Cited by 107
“Indiscriminate use of antibiotics to alter the oral microbiome comes with the risks of creating multi-drug-resistant organisms, adverse drug reactions, and dysbiosis of the microbiota, which may lead to complications such as Clostridioides difficile diarrhea.(95)”
BackgroundBlount, K., Megyola, C. M., Plummer, M. S., Osterman, D. G., O'Connell, T., Aristoff, P. A., Quinn, C. L., Chrusciel, R. A., Poel, T. J., Schostarez, H. J., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01282-15 · Cited by 96
Ren, W., Yin, J., Xiao, H., Chen, S., Liu, G., Tan, B., Li, N., Peng, Y., Li, T., Zeng, B., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00685 · Cited by 103
“The intestinal microbiota has critical importance in intestinal infections by increasing colonization resistance and promoting pathogen clearance after infection (1, 2).”
BackgroundComposition of human faecal microbiota in resistance to Campylobacter infection
Kampmann, C., Dicksved, J., Engstrand, L., & Rautelin, H. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.09.004 · Cited by 94
“in general, and that after antimicrobial use in particular, are known to be the central factors leading to the development of Clostridium difficile infection [4], only very recently some specific bacterial compositions of the gut community have been connected to this infection [5,6].”
BackgroundAn ecological framework to understand the efficacy of fecal microbiota transplantation
Xiao, Y., Angulo, M. T., Lao, S., Weiss, S. T., & Liu, Y.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-17180-x · Cited by 89
Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis
Al-Qadami, G. H., Sebille, Y. Z. A. V., Le, H. V., & Bowen, J. M. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1595586 · Cited by 94
“The loss of colonization resistance and imbalanced immune responses during dysbiosis contributes to the pathogenesis of Clostridium difficile infection [26].”
BackgroundAlternative approaches to treat bacterial infections: targeting quorum-sensing
Piewngam, P., Chiou, J., Chatterjee, P., & Otto, M. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1750951 · Cited by 79
“difficile that occur due to intestinal dysbiosis as a result of antibiotic use [115].”
BackgroundWilling, S. E., Candela, T., Shaw, H. A., Seager, Z., Mesnage, S., Fagan, R. P., & Fairweather, N. F. (2015) · Molecular Microbiology · doi:10.1111/mmi.12958 · Cited by 75
“difficile to proliferate and cause disease (Seekatz and Young, 2014).”
BackgroundInfluentialFunctional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation
Fujimoto, K., Kimura, Y., Allegretti, J. R., Yamamoto, M., Zhang, Y., Katayama, K., Tremmel, G., Kawaguchi, Y., Shimohigoshi, M., Hayashi, T., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.013 · Cited by 89
SanMiguel, A. J., Meisel, J. S., Horwinski, J., Zheng, Q., & Grice, E. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00774-17 · Cited by 79
“Clostridium difficile is perhaps the best-studied representation of this effect (36).”
BackgroundThe zoonotic potential of Clostridium difficile from small companion animals and their owners
Rabold, D., Espelage, W., Sin, M. A., Eckmanns, T., Schneeberg, A., Neubauer, H., Möbius, N., Hille, K., Wieler, L. H., Seyboldt, C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193411 · Cited by 82
“While age, hospitalization and prior antibiotic exposure are confirmed risk factors for CDI in humans [22], factors associated with the isolation of C.”
BackgroundStable core virome despite variable microbiome after fecal transfer
Broecker, F., Russo, G., Klumpp, J., & Moelling, K. (2017) · Gut Microbes · doi:10.1080/19490976.2016.1265196 · Cited by 81
“FMT-mediated cure of rCDI is associated with expanded beneficial Bacteroidetes and Firmicutes bacteria in the patient’s intestine, whereas detrimental Proteobacteria populations contract.(3,4) The 10(14) gut bacteria per individual(5) are conventionally considered the most relevant component of FMT.”
BackgroundBoix, V., Fedorak, R. N., Mullane, K. M., Pesant, Y., Stoutenburgh, U., Jin, M., Adedoyin, A. B., Chesnel, L., Güriş, D., Larson, K. B., et al. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw275 · Cited by 76
“Sparing of the Gram-negatives and bacteroidetes during CDI therapy is hypothesized to favor recovery of a healthy microbiota and to lower CDI recurrence [13].”
BackgroundDubberke, E. R., Mullane, K. M., Gerding, D. N., Lee, C. H., Louie, T. J., Guthertz, H., & Jones, C. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw133 · Cited by 75
“difficile, among others, to colonize and proliferate [24].”
BackgroundGut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface
Sehgal, K., & Khanna, S. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284821994736 · Cited by 80
Kumar, R., Yi, N., Zhi, D., Eipers, P., Goldsmith, K. T., Dixon, P., Crossman, D. K., Crowley, M. R., Lefkowitz, E. J., Rodriguez, J. M., et al. (2017) · npj Biofilms and Microbiomes · doi:10.1038/s41522-017-0020-7 · Cited by 72
Clostridioides difficile LuxS mediates inter-bacterial interactions within biofilms
Slater, R. T., Frost, L. R., Jossi, S. E., Millard, A. D., & Unnikrishnan, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-46143-6 · Cited by 74
“correlate negatively [8-10], and Lactobacilli, Aerococcaceae, Enterobacteriaceae, and Clostridium correlate positively to C.”
BackgroundGut Microbiota Composition Associated with Clostridioides difficile Colonization and Infection
Martínez, E. D., Taminiau, B., Rodriguez, C., & Daube, G. (2022) · Pathogens · doi:10.3390/pathogens11070781 · Cited by 75
High-resolution profiling of the gut microbiome reveals the extent of Clostridium difficile burden
Daquigan, N., Seekatz, A. M., Greathouse, K. L., Young, V. B., & White, J. R. (2017) · npj Biofilms and Microbiomes · doi:10.1038/s41522-017-0043-0 · Cited by 69
“The development of microbial-based therapeutics, such as fecal microbiota transplantation (FMT) and combinations of selected microbes for the treatment of recurrent CDI suggests that mixtures of commensal microbes may be routinely utilized in the future as an alternative to powerful antibiotics.(6,7) Microbiome profil…”
BackgroundSelf-citationUsing an Endogenous CRISPR-Cas System for Genome Editing in the Human Pathogen Clostridium difficile
Maikova, A., Kreis, V., Boutserin, A., Severinov, K., & Soutourina, O. A. (2019) · Applied and Environmental Microbiology · doi:10.1128/aem.01416-19 · Cited by 72
“difficile to colonize the intestinal tract after the germination of preexisting or acquired spores (2, 6).”
BackgroundCheng, C. C., Duar, R. M., Lin, X., Perez-Munoz, M. E., Tollenaar, S., Oh, J.-H., van Pijkeren, J.-P., Li, F., van Sinderen, D., Gänzle, M. G., et al. (2020) · Applied and Environmental Microbiology · doi:10.1128/aem.00190-20 · Cited by 65
Clostridium difficile infection in returning travellers
Stevens, A. M., Esposito, D. H., Stoney, R. J., Hamer, D. H., Flores‐Figueroa, J., Bottieau, E., Connor, B. A., Gkrania‐Klotsas, E., Goorhuis, A., Hynes, N. A., et al. (2017) · Journal of Travel Medicine · doi:10.1093/jtm/taw099 · Cited by 66
“difficile colitis.(17,18) Aside from antibiotic use, other factors that influence the gut microbiota include changes in diet, both intestinal and extra-intestinal infections, use of nonantimicrobial medications (including agents that affect gut motility), and changes in environment, many of which may be encountered du…”
Gut Microbiota and Clostridium difficile: What We Know and the New Frontiers
Piccioni, A., Rosa, F., Manca, F., Pignataro, G., Zanza, C., Savioli, G., Covino, M., Ojetti, V., Gasbarrini, A., Franceschi, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113323 · Cited by 70
“However, every change in the microbial environment could bring spore germination, CD growth, and toxin production [48].”
BackgroundSmart Capsule for Targeted Proximal Colon Microbiome SamplingPreprint
Nejati, S., Wang, J., Sedaghat, S., Balog, N. K., Long, A. M., Heredia-Rivera, U., Kasi, V., Park, K., Johnson, J. S., Verma, M. S., et al. (2022) · SSRN Electronic Journal · doi:10.1016/j.actbio.2022.09.050 · Cited by 62
The battle for iron in enteric infections
Sousa Gerós, A., Simmons, A., Drakesmith, H., Aulicino, A., & Frost, J. N. (2020) · Immunology · doi:10.1111/imm.13236 · Cited by 58
Discovery of new type I toxin–antitoxin systems adjacent to CRISPR arrays in Clostridium difficile
Maikova, A., Johann, P., Boudry, P., Hajnsdorf, E., Kint, N., Monot, M., Poquet, I., Martin‐Verstraete, I., Dupuy, B., & Soutourina, O. A. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky124 · Cited by 62
“difficile from preexisting or acquired spores (10,11).”
Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?
Targownik, L. E. (2018) · The American Journal of Gastroenterology · doi:10.1038/ajg.2018.29 · Cited by 61
Regulation of Clostridium difficile Spore Formation by the SpoIIQ and SpoIIIA Proteins
Fimlaid, K. A., Jensen, O., Donnelly, M. L., Siegrist, M. S., & Shen, A. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005562 · Cited by 57
“difficile spores are ingested by susceptible hosts, they germinate in the gut and outgrow to form toxin-secreting vegetative cells [7,11,12].”
BackgroundRidinilazole: a novel therapy for Clostridium difficile infection
Vickers, R. J., Tillotson, G., Goldstein, E. J. C., Citron, D. M., Garey, K. W., & Wilcox, M. H. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.026 · Cited by 54
“This antibiotic-inducedmicrobial imbalance (or dysbiosis) is thought to lead to functional changes in the host intestinal environment that impair colonisation resistance, thereby conferring susceptibility to CDI [80,86].”
BackgroundLamendella, R., Wright, J., Hackman, J., McLimans, C. J., Toole, D. R., Rubio, W. B., Drucker, R., Wong, H. T., Sabey, K. A., Hegarty, J. P., et al. (2018) · mSphere · doi:10.1128/msphere.00572-17 · Cited by 54
“Studies focused on metagenomics have characterized the dysbiosis of CDI as being associated with a significant reduction in taxa belonging to the Bacteroidetes and Firmicutes phyla, with a concomitant relative abundance of Proteobacteria (3, 4).”
BackgroundSelective colonization ability of human fecal microbes in different mouse gut environments
Zhou, W. L., Chow, K.-H., Fleming, E. S., & Oh, J. (2018) · The ISME Journal · doi:10.1038/s41396-018-0312-9 · Cited by 60
Yoon, S., Yu, J., McDowell, A., Kim, S. H., You, H. J., & Ko, G. (2017) · Journal of Microbiology · doi:10.1007/s12275-017-7340-4 · Cited by 49
Contribution of sulfate-reducing bacteria to homeostasis disruption during intestinal inflammation
Figliuolo, V. R., Coutinho‐Silva, R., & Coutinho, C. M. L. M. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.11.009 · Cited by 57
Gut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults
Vasilescu, I.-M., Chifiriuc, M. C., Pîrcălăbioru, G. G., Filip, R., Bolocan, A., Lazăr, V., Diţu, L.-M., & Bleoţu, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.651081 · Cited by 61
“From the mentioned components, Ruminococcus and Bifidobacterium have been reported to exhibit protective roles against CDI (Seekatz and Young, 2014; Kho and Lal, 2018).”
BackgroundDevelopment of the infant intestinal microbiome: A bird's eye view of a complex process
Meropol, S. B., & Edwards, A. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21114 · Cited by 59
“By killing off colonizing organisms, antibiotics can promote overgrowth of competing antibiotic-resistant pathologic organisms (Jernberg et al., 2007; Seekatz and Young, 2014).”
Kelly, B. J., & Tebas, P. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.09.002 · Cited by 54
Pakpour, S., Bhanvadia, A., Zhu, R., Amarnani, A., Gibbons, S. M., Gurry, T., Alm, E. J., & Martello, L. A. (2017) · Microbiome · doi:10.1186/s40168-017-0368-1 · Cited by 49
Han, S., Yi, J., Kim, J., Lee, S., & Moon, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212626 · Cited by 53
Modeling the Role of the Microbiome in Evolution
Huitzil, S., Sandoval‐Motta, S., Frank, A., & Aldana, M. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01836 · Cited by 49
Wilcox, M. H., McGovern, B., & Hecht, G. A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa114 · Cited by 49
“bacteria, inhibit vegetative bacterial growth [5].”
Kim, J., Cho, Y., Seo, M.-R., Bae, M. H., Kim, B., Rho, M., & Pai, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-74090-0 · Cited by 48
Microbiome modulates intestinal homeostasis against inflammatory diseases
Sun, X., & Jia, Z. (2018) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2018.10.014 · Cited by 48
Szőke, H., Kovács, Z., Bókkon, I., Vagedes, J., Erdöfi-Szabó, A., Hegyi, G., Sterner, M.-G., Kiss, Á., & Kapócs, G. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0095 · Cited by 49
Broecker, F., Klumpp, J., & Moelling, K. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13100 · Cited by 48
The sex-specific interaction of the microbiome in neurodegenerative diseases
Cox, L. M., Abou-El-Hassan, H., Maghzi, A. H., Vincentini, J., & Weiner, H. L. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146385 · Cited by 42
“When the microbiota become depleted through heavy antibiotic exposure, pathogenic bacteria such as Clostridium difficile can overgrow and result in serious intestinal infection (Seekatz and Young, 2014).”
BackgroundClostridioides difficile Infection
Stewart, D. B. (2020) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0040-1701228 · Cited by 43
Risk factors for esophageal cancer: emphasis on infectious agents
El-Zimaity, H. M. T., Pilato, V. D., Ringressi, M. N., Brčić, I., Rajendra, S., Langer, R., Dislich, B., Tripathi, M., Guindi, M. M., & Riddell, R. H. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13858 · Cited by 44
Golić, N., Veljović, K., Popović, N., Đokić, J., Strahinić, I., Mrvaljević, I., & Terzić-Vidojević, A. (2017) · BMC Microbiology · doi:10.1186/s12866-017-1015-5 · Cited by 45
“difficile is the leading etiological agent of microbiota dysbiosis-associated diarrhoea caused by antibiotic use [3].”
BackgroundHutton, M. L., Cunningham, B. A., Mackin, K. E., Lyon, S. A., James, M. L., Rood, J. I., & Lyras, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-03982-5 · Cited by 39
Hamilton, M. K., Wall, E. S., Robinson, C. D., Guillemin, K. J., & Eisen, J. S. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1009989 · Cited by 40
“In some instances, the initial trigger is an infectious microbe, such as Clostridium difficile, which can cause severe and persistent inflammation and dysbiosis [70].”
BackgroundAcid-Suppressive Therapy and Risk of Infections: Pros and Cons
Fisher, L., & Fisher, A. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0519-y · Cited by 43
Byproduct Cross Feeding and Community Stability in an In Silico Biofilm Model of the Gut Microbiome
Henson, M. A., & Phalak, P. (2017) · Processes · doi:10.3390/pr5010013 · Cited by 40
“For example, Clostridium difficile infections are often attributed to the use of broad spectrum antibiotics that inadvertently alter microbiota diversity and species composition, thereby reducing colonization resistance to pathogen invasion [44,45].”
BackgroundClostridium difficile forms variable biofilms on abiotic surface
Pantaleon, V., Monot, M., Eckert, C., Hoÿs, S., Collignon, A., Janoir, C., & Candela, T. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.05.006 · Cited by 36
Cao, Y., Wang, L., Ke, S., Villafuerte-Gálvez, J., Pollock, N. R., Barrett, C. G., Sprague, R., Daugherty, K., Xu, H. J., Lin, Q., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.069 · Cited by 41
Etienne‐Mesmin, L., Chassaing, B., Adekunle, O., Mattei, L. M., Bushman, F. D., & Gewirtz, A. T. (2017) · Gut · doi:10.1136/gutjnl-2016-313510 · Cited by 36
“Susceptibility to CDI is primarily conferred by use of antibiotics that ablate the microbiota, which normally serves as a strong barrier to C. difficile colonization [8, 9, 10, 11, 12].”
BackgroundEpidemiological and genomic characterization of community-acquired Clostridium difficile infections
Thornton, C. S., Rubin, J. E., Greninger, A. L., Peirano, G., Chiu, C. Y., & Pillai, D. R. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3337-9 · Cited by 35
Nycz, B. T., Dominguez, S. R., Friedman, D., Hilden, J. M., Ir, D., Robertson, C. E., & Frank, D. N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191232 · Cited by 39
Mooyottu, S., Flock, G. H., Upadhyay, A., Upadhyaya, I., Maas, K. R., & Venkitanarayanan, K. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00625 · Cited by 39
“Moreover, agerelated senescence in the immune status of the elderly, along with frequent hospital visits during old age contribute to a detrimental alteration in the gut microbiome and subsequent colonization of C. difficile (Seekatz and Young, 2014).”
BackgroundCohen, S. H., Louie, T., Sims, M. D., Wang, E. E. L., Memisoglu, A., McGovern, B., & Moltke, L. L. V. (2022) · JAMA · doi:10.1001/jama.2022.16476 · Cited by 34
Adult vaccination: Current recommendations and future prospects
Swanson, K. A., Schmitt, H. J., Jansen, K. U., & Anderson, A. S. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.35858 · Cited by 33
“difficile; however antibiotic treatment can disrupt this natural defense leading to increased infection and disease risk.(36) Once the organism colonizes the gut it produces toxins that cause the patient to develop severe gastroenteritis, diarrhea and can irreversibly damage the intestines.”
BackgroundThe New Kid on the Block: A Specialized Secretion System during Bacterial Sporulation
Morlot, C., & Rodrigues, C. D. A. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.01.001 · Cited by 32
From Nursery to Nursing Home: Emerging Concepts in Clostridioides difficile Pathogenesis
Smith, A. B., Ocaña, J. S., & Zackular, J. P. (2020) · Infection and Immunity · doi:10.1128/iai.00934-19 · Cited by 33
“The primary risk factors for CDI are broad-spectrum antibiotic treatments, length of hospital stay, increasing age, and underlying comorbidities (4).”
BackgroundWu, Q., Chen, T., El-Nezami, H. S., & Savidge, T. (2020) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2020.04.007 · Cited by 34
Reed, A. D., Fletcher, J. R., Huang, Y. Y., Thanissery, R., Rivera, A. J., Parsons, R., Stewart, A. K., Kountz, D. J., Shen, A., Balskus, E. P., et al. (2022) · mSphere · doi:10.1128/msphere.00926-21 · Cited by 31
DuPont, H. L., Dupont, A. W., & Tillotson, G. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241253089 · Cited by 31
“Antibiotic classes differ in their potential to deplete the gut microbiome, predisposing patients to CDI and recurrences of CDI 11,12 and producing immune and inflammatory events.”
BackgroundPitfalls in Diagnosis of Pediatric Clostridium difficile Infection
Sammons, J. S., & Toltzis, P. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.05.010 · Cited by 30
Cançado, G. G. L., Silva, R. O. S., Rupnik, M., Nader, A. P., de Carvalho, J. S., Paixao, G. M., Resende, B., Lobato, F. C. F., & Vilela, E. G. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.08.005 · Cited by 31
Dong, N., Li, Z., Qin, P., Qiang, C., Yang, J., Niu, Y., Niu, X. R., Liu, X., Wang, W. G., Wen, B., et al. (2022) · Journal of Hospital Infection · doi:10.1016/j.jhin.2022.09.004 · Cited by 33
Type I Toxin-Antitoxin Systems in Clostridia
Soutourina, O. A. (2019) · Toxins · doi:10.3390/toxins11050253 · Cited by 29
Boudry, P., Piattelli, E., Drouineau, E., Johann, P., Boutserin, A., Lejars, M., Hajnsdorf, E., Monot, M., Dupuy, B., Martin‐Verstraete, I., et al. (2021) · RNA Biology · doi:10.1080/15476286.2021.1882180 · Cited by 30
“adults from CDI, since antibiotic treatments induce a colonic dysbiosis state that subsequently facilitates the development of this pathogen from acquired or pre-existing spores in healthy carriers [2,3].”
BackgroundSchmidt, C. J., Wenndorf, K., Ebbers, M., Volzke, J., Müller, M., Strübing, J., Kriebel, K., Kneitz, S., Kreikemeyer, B., & Müller‐Hilke, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571049 · Cited by 30
Dong, Q., Lin, H., Allen, M.-M., Garneau, J. R., Sia, J. K., Smith, R. C., Haro, F., McMillen, T. A., Pope, R. L., Metcalfe, C. K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112861 · Cited by 29
Self-citationFecal Microbiota Transplantation: Information for the Pediatrician
Oliva‐Hemker, M. M., Kahn, S. A., Steinbach, W. J., SECTION ON GASTROENTEROLOY, H., Cohen, M. B., Brumbaugh, D. E., Cole, C. R., Dotson, J. L., Harpavat, S., Lightdale, J. R., et al. (2023) · PEDIATRICS · doi:10.1542/peds.2023-062922 · Cited by 30
Gut microbiota and Clostridium difficile infections
Lagier, J. (2016) · Human Microbiome Journal · doi:10.1016/j.humic.2016.10.003 · Cited by 28
Cull, C. A., Singu, V., Cull, B. J., Lechtenberg, K. F., Amachawadi, R. G. G., Schutz, J. S., & Bryan, K. A. (2022) · Antibiotics · doi:10.3390/antibiotics11111513 · Cited by 25
In the Age of Synthetic Biology, Will Antimicrobial Peptides be the Next Generation of Antibiotics?
Jaumaux, F., de Cadiñanos, L. P. G., & Gabant, P. (2020) · Antibiotics · doi:10.3390/antibiotics9080484 · Cited by 28
“A well-studied example of microbial dysbiosis (imbalance in the composition and function of microbes) involves the intestinal disorder caused by sudden proliferation of latent Clostridium difficile bacteria that are normally held in check by other gut microbes as a result of removal of the suppressing microbes due to…”
Background
Metadata
- Authors
- Seekatz, A. M., & Young, V. B.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Young, Vincent B.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-07-18
- Volume
- 124
- Issue
- 10
- Pages
- 4182-4189
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4191019
- OpenAlex
- W2020298266
- Cited by
- 255
- References
- 100
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 15 · 2023: 16 · 2022: 22 · 2021: 17 · 2020: 31 · 2019: 23 · 2018: 28 · 2017: 28 · 2016: 19 · 2015: 13 · 2014: 4
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Michigan (48109)
- National Institutes of Health
- College of Pharmacy, University of Michigan
- Medical School, University of Michigan
- National Institute of Allergy and Infectious Diseases (U19AI090871)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Clostridium difficile infection, gut microbiota, colonization resistance, antibiotic-induced dysbiosis, recurrent Clostridium difficile infection, biologic therapy, nosocomial infections
- MeSH terms
- Age Factors, Aged, Animals, Clostridium Infections, Humans, Immune System, Recurrence, Risk Factors, Spores, Bacterial, Clostridioides difficile, Gastrointestinal Tract, Mice, Microbiota, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.